紫杉醇在肺癌、胸腺癌、食道癌、淋巴瘤等多种肿瘤的治疗中得到广泛应用。但紫杉醇水溶性差，传
统制剂采用聚氧乙烯蓖麻油( Cremophor EL) 与无水乙醇( 1 ∶1) 为增溶溶媒，临床使用中引起的不良反应较多。
为提高紫杉醇制剂的治疗效果，降低不良反应，国内外学者致力于紫杉醇制剂学的研究。纳米制剂是现代药物
制剂研究的前沿和热点，本文就紫杉醇纳米制剂的开发和应用进展进行综述。

Paclitaxel is widely used in the treatment of lung cancer，breast cancer，esophageal
cancer， lymphoma and other tumor． Clinical use of paclitaxel is limited by its poor aqueous solubility．
Cremophor EL and ethanol ( 1 ∶ 1 ) are used as solvent in traditional administration of paclitaxel．
However，Cremophor EL has adverse reactions in clinic． Some alternative formulations have been
studied to increase its therapeutic index and decrease toxicity and hypersensitivity． Nanoparticle formulation
is the frontier and focus of modern pharmaceutical drug delivery system． In this paper， the latest
development and application of paclitaxel nanoparticle formulations were reviewed．

Ｒ73

 收稿日期:2014－09－05; 修回日期:2014－10－17
基金项目:国家自然科学基金( 81260615)
作者简介:张英( 1980－) ，女，蒙古族，内蒙古医科大学药学院实验师。
通讯作者:王晓琴，教授． 中药学博士，E－mail: nywangxiaoqin@163． com 内蒙古医科大学药学院， 010110